Cingulate Successfully Manufactures Clinical Supply, Initiation Of Pediatric Phase 3 Studies To Commence In July And August
Portfolio Pulse from Happy Mohamed
Cingulate Inc. (NASDAQ:CING) has successfully manufactured the clinical supply for upcoming pivotal Phase 3 trials of its lead candidate, CTx-1301 (dexmethylphenidate), for the treatment of attention deficit/hyperactivity disorder (ADHD). The trials are set to begin in July and August. The company recently completed a Phase 3 adult onset and duration study of CTx-1301 with results expected in 3Q 2023. If the trials are successful, Cingulate plans to submit a New Drug Application (NDA) for CTx-1301 in mid-2024.
June 29, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cingulate Inc. has successfully manufactured the clinical supply for its upcoming Phase 3 trials of CTx-1301, a treatment for ADHD. This could potentially lead to a new product launch if the trials are successful.
The successful manufacturing of the clinical supply for the Phase 3 trials of CTx-1301 is a significant step for Cingulate Inc. This indicates that the company is on track with its development timeline, which could potentially lead to a new product launch if the trials are successful. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100